MAPT and Alzheimer disease: This makes the inhibition of Aβand tau aggregation an attractive mechanism of action for the disease-modifyingtreatment of AD.46 Multisite AChE inhibitorsconsisting of two (hetero)aromatic rings linked through a suitabletether also inhibit tau aggregation, usually with potencies similarto those found for Aβ42 aggregation (Figure 11).